3-TRENBOMED 150, Deus Medical (Trenbolone Blend)

$130.00

Deus Medical 3-TRENBOMED 150 contains a specialized 150 mg/mL multi-ester Trenbolone blend featuring Trenbolone Acetate (50 mg), Trenbolone Enanthate (50 mg), and Trenbolone Hexahydrobenzylcarbonate (50 mg) per 1 mL ampoule. Supplied in a pack of 10 sterile ampoules, this high-purity injectable formulation is engineered for advanced laboratory models studying sustained androgen receptor saturation, nitrogen retention, and metabolic signaling efficiency across fast and extended release phases. Strictly for laboratory research use only.

Description

Deus Medical 3-TRENBOMED 150 is a premium multi-ester injectable anabolic research compound standardized at a total concentration of 150 mg/mL. Packaged in a box of 10 single-dose ampoules (1 mL per ampoule), this formulation combines fast-acting, medium-acting, and long-acting Trenbolone esters to establish a stable, multi-phase pharmacokinetic release profile.

By integrating three esterified variations of 19-norandrostenedione, 3-TRENBOMED 150 eliminates the steep concentration fluctuations associated with single-ester administration in experimental models. Trenbolone exhibits exceptionally strong androgen receptor affinity and anabolic potency without undergoing aromatization into estrogen.

Key Specifications & Active Ingredients

Ā Total Concentration: 150 mg/mL

Ā Trenbolone Acetate: 50 mg/mL (Fast-acting short ester)

Ā Trenbolone Enanthate: 50 mg/mL (Medium-acting long ester)

Ā Trenbolone Hexahydrobenzylcarbonate: 50 mg/mL (Slow-release long ester)

Ā Volume: 10 Ampoules x 1 mL

Ā Manufacturer: Deus Medical

Ā Formulation: Injectable Solution in Carrier Oil

Ā Classification: Anabolic-Androgenic Research Compound

Dosage & Research Administration Protocol

Ā Experimental Standard Dosage: In advanced endocrine and physiological research models, standard protocol ranges evaluate total compound administration between 150 mg and 300 mg per week (1 to 2 mL total volume weekly).

Ā Administration Frequency: Due to the fast-acting Acetate ester component, doses in multi-phase models are typically divided into twice-weekly intramuscular injections (e.g., 0.5 mL to 1 mL every 3 to 4 days) to maintain steady-state serum concentration.

Ā Research Model Duration: Typical research observation periods range from 8 to 12 weeks maximum due to compound potency and severe HPTA suppression dynamics.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “3-TRENBOMED 150, Deus Medical (Trenbolone Blend)”

Your email address will not be published. Required fields are marked *

Shipping and Delivery

MAECENAS IACULIS

Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoqueĀ dui.

ADIPISCING CONVALLIS BULUM

  • Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
  • Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
  • Diam parturient dictumst parturient scelerisque nibh lectus.

Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisqueĀ vestibulum amet elit ut volutpat.